Stock EDIT EDITAS MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
5.32 USD +1.92% Intraday chart for Editas Medicine, Inc. -3.10% -47.48%
03-13 Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
02-29 Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating MT

Business Summary

Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Number of employees: 265

Sales per Business

USD in Million2022Weight2023Weight Delta
Genome Editing Technology
100.0 %
20 100.0 % 78 100.0 % +296.32%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
20 100.0 % 78 100.0 % +296.32%

Managers

Managers TitleAgeSince
Gilmore O’Neill CEO
 Chief Executive Officer 59 31/05/22
Erick Lucera DFI
 Director of Finance/CFO 57 16/05/23
Linda Burkly CTO
 Chief Tech/Sci/R&D Officer - 23/07/23
Mei Baisong CTO
 Chief Tech/Sci/R&D Officer 60 17/07/22
Chi Li LAW
 General Counsel - 13/06/21
Linea Aspesi HRO
 Human Resources Officer - 31/01/23
Charlene Stern LAW
 General Counsel - 31/12/12
Kate X. Zhang PRN
 Corporate Officer/Principal - 30/09/18
Caren Deardorf PRN
 Corporate Officer/Principal 59 25/09/23

Members of the board

Members of the board TitleAgeSince
Emma Reeve CHM
 Chairman 63 02/09/21
David Scadden BRD
 Director/Board Member 71 05/02/19
Akshay Vaishnaw BRD
 Director/Board Member 61 27/07/16
Andrew Hirsch BRD
 Director/Board Member 53 29/05/17
Jessica Hopfield BRD
 Director/Board Member 59 15/02/18
Elliott Levy BRD
 Director/Board Member 64 10/04/23
Bernadette Connaughton BRD
 Director/Board Member 65 25/10/21
Gilmore O’Neill CEO
 Chief Executive Officer 59 31/05/22
Meeta Chatterjee BRD
 Director/Board Member 69 16/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,234,710 81,969,942 ( 99.68 %) 0 99.68 %

Shareholders

NameEquities%Valuation
SSgA Funds Management, Inc.
10.71 %
8,760,151 10.71 % 65 M $
Vanguard Fiduciary Trust Co.
10.34 %
8,461,857 10.34 % 63 M $
BlackRock Advisors LLC
8.819 %
7,215,089 8.819 % 54 M $
Deep Track Capital LP
6.690 %
5,473,086 6.690 % 41 M $
STATE STREET CORPORATION
6.196 %
5,069,543 6.196 % 38 M $
Dimensional Fund Advisors LP
2.924 %
2,392,396 2.924 % 18 M $
Pictet Asset Management Holding SA
2.422 %
1,981,679 2.422 % 15 M $
Geode Capital Management LLC
2.324 %
1,901,735 2.324 % 14 M $
Millennium Management LLC
1.944 %
1,590,809 1.944 % 12 M $
Two Sigma Investments LP
1.781 %
1,457,394 1.781 % 11 M $

Company contact information

Editas Medicine, Inc.

11 Hurley Street

02141, Cambridge

+617 401 9000

http://www.editasmedicine.com
address Editas Medicine, Inc.(EDIT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Editas Medicine, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
5.32 USD
Average target price
15.4 USD
Spread / Average Target
+189.47%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
EDITAS MEDICINE, INC. Stock Editas Medicine, Inc.
-47.48% 437M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. EDIT Stock
  4. Company Editas Medicine, Inc.